Milton H.  Werner net worth and biography

Milton Werner Biography and Net Worth

Dr. Milton Werner is the President and Chief Executive Officer of Inhibikase Therapeutics, a company developing novel protein kinase inhibitor therapeutics to treat neurodegenerative disease and viral infection inside and outside of the brain. Previously, Dr. Werner served as Vice President of Research at Celtaxsys, a cell-free immunotherapeutics company. From September 1996 until June 2007, Dr. Werner was a Head of the Laboratory of Molecular Biophysics at The Rockefeller University in New York City. Throughout his scientific career, Dr. Werner has been an innovator integrating chemistry, physics, and biology into a comprehensive approach to solving problems in medicine, including an explanation of the origin of “maleness” in humans, the mechanistic basis of several forms of leukemia and lymphoma and, more recently, the development of therapeutics that can halt and potentially reverse functional loss in neurodegenerative disease.

Dr. Werner is the author or co-author of more than 70 research articles, reviews, and book chapters and has given lectures on his research work throughout the world. He is the recipient of numerous private and public research grants totaling more than $30 million. He is the recipient of several awards, including the Naito Memorial Foundation Prize, the Young Investigator Award from the Sidney Kimmel Cancer Foundation, the Research Chair from the Brain Tumor Society, and a $1 million Distinguished Young Scholars in Medical Research Award from the W. M. Keck Foundation. Dr. Werner received his Doctor of Philosophy in Chemistry from the University of California, Berkeley, and his Bachelor of Science in Biochemistry from the University of Southern California, and he was an NIH intramural postdoctoral fellow prior to his tenure at the Rockefeller University.

What is Milton H. Werner's net worth?

The estimated net worth of Milton H. Werner is at least $2.14 million as of August 16th, 2022. Dr. Werner owns 889,238 shares of Inhibikase Therapeutics stock worth more than $2,143,064 as of March 28th. This net worth evaluation does not reflect any other assets that Dr. Werner may own. Additionally, Dr. Werner receives an annual salary of $658,190.00 as CEO at Inhibikase Therapeutics. Learn More about Milton H. Werner's net worth.

How old is Milton H. Werner?

Dr. Werner is currently 60 years old. There are 1 older executives and no younger executives at Inhibikase Therapeutics. Learn More on Milton H. Werner's age.

What is Milton H. Werner's salary?

As the CEO of Inhibikase Therapeutics, Inc., Dr. Werner earns $658,190.00 per year. Learn More on Milton H. Werner's salary.

How do I contact Milton H. Werner?

The corporate mailing address for Dr. Werner and other Inhibikase Therapeutics executives is , , . Inhibikase Therapeutics can also be reached via phone at 678-392-3419 and via email at [email protected]. Learn More on Milton H. Werner's contact information.

Has Milton H. Werner been buying or selling shares of Inhibikase Therapeutics?

Milton H. Werner has not been actively trading shares of Inhibikase Therapeutics within the last three months. Most recently, on Tuesday, August 16th, Milton H. Werner bought 833 shares of Inhibikase Therapeutics stock. The stock was acquired at an average cost of $4.80 per share, with a total value of $3,998.40. Following the completion of the transaction, the chief executive officer now directly owns 889,238 shares of the company's stock, valued at $4,268,342.40. Learn More on Milton H. Werner's trading history.

Milton H. Werner Insider Trading History at Inhibikase Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2022Buy833$4.80$3,998.40889,238View SEC Filing Icon  
5/27/2022Buy833$5.88$4,898.04888,405View SEC Filing Icon  
5/20/2022Buy1,666$3.60$5,997.60887,572View SEC Filing Icon  
11/17/2021Buy3,931$11.82$46,464.42View SEC Filing Icon  
See Full Table

Milton H. Werner Buying and Selling Activity at Inhibikase Therapeutics

This chart shows Milton H Werner's buying and selling at Inhibikase Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inhibikase Therapeutics Company Overview

Inhibikase Therapeutics logo
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Read More

Today's Range

Now: $2.19
Low: $2.08
High: $2.44

50 Day Range

MA: $2.38
Low: $1.72
High: $3.21

2 Week Range

Now: $2.19
Low: $0.79
High: $4.56

Volume

95,321 shs

Average Volume

147,109 shs

Market Capitalization

$13.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19